Sensei to ditch its lead candidate and cut workforce amidst strategic review
Sensei Biotherapeutics is set to abandon its sole clinical-stage asset solnerstotug as it prepares to cut its workforce and consider…
Oncology
-
-
Teva to collaborate with Fosun Pharma for TEV-56278
Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed…
-
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in…
-
NICE approves GSK’s belantamab mafodotin for blood cancer
The National Health Service (NHS) England is set to become the first health system globally to offer the "Trojan horse"…
-
Antares Therapeutics gains $177m for cancer medicines development
Antares Therapeutics has secured $177m in a Series A financing round for the development of precision medicines to treat cancer…
-
ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
Data from the Phase II ELM-2 trial was presented at the American Society of Hematology (ASH) 2024 Annual Meeting, held…
-
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the US Food and Drug Administration (FDA), marking “an important milestone” in…
-
NCCN visits Vietnam in continued cancer care collaboration
Leaders from the National Comprehensive Cancer Network (NCCN) alliance of US cancer centres are in Vietnam today (1 November) as…
-
Bladder cancer diagnoses to top 300,000 in major markets by 2033
The number of incident cases of bladder cancer in the eight major markets is set to increase, with men and…
-
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Lyell Immunopharma has entered a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage biotechnology company specialising in chimeric antigen…
